CER-001

Synthetic HDL mimetic peptide

CER-001
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

CER-001 is a synthetic high-density lipoprotein (HDL) mimetic peptide designed to mimic the structure and function of natural HDL particles. It is primarily developed for its potential therapeutic effects in cardiovascular diseases by promoting reverse cholesterol transport.

Mechanism of Action

Mechanism of action of CER-001

CER-001 is engineered to simulate the beneficial properties of HDL, often referred to as "good cholesterol." It is composed of a combination of phospholipids and a peptide that mimics apolipoprotein A-I (ApoA-I), the main protein component of HDL. The primary mechanism of action involves the promotion of reverse cholesterol transport, a process by which excess cholesterol is removed from peripheral tissues and transported to the liver for excretion.

The synthetic HDL particles formed by CER-001 facilitate the uptake of cholesterol from macrophages in atherosclerotic plaques, potentially reducing plaque size and stabilizing the plaques to prevent rupture, which can lead to myocardial infarction or stroke.

Clinical Development

CER-001 has been investigated in several clinical trials to assess its efficacy and safety in patients with cardiovascular diseases. The trials have focused on its ability to reduce atherosclerotic plaque burden and improve cardiovascular outcomes. While some studies have shown promising results in terms of plaque regression, the overall clinical benefits in terms of reducing cardiovascular events remain under investigation.

Potential Applications

The primary application of CER-001 is in the treatment of cardiovascular diseases, particularly in patients with coronary artery disease and those at high risk of cardiovascular events. By enhancing reverse cholesterol transport, CER-001 aims to provide a novel therapeutic approach to managing dyslipidemia and reducing the risk of atherosclerosis-related complications.

Challenges and Considerations

Despite its potential, the development of CER-001 faces several challenges. The complexity of mimicking natural HDL function and the variability in patient response are significant hurdles. Additionally, the cost of production and the need for extensive clinical trials to establish long-term safety and efficacy are important considerations for its future development.

Related Pages

• High-density lipoprotein
• Apolipoprotein A-I
• Reverse cholesterol transport
• Cardiovascular disease
• Atherosclerosis